Literature DB >> 21351303

The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy.

Kevin L Winthrop1, Roger Baxter, Liyan Liu, Bentson McFarland, Donald Austin, Cara Varley, LeAnn Radcliffe, Eric Suhler, Dongsoek Choi, Lisa J Herrinton.   

Abstract

PURPOSE: Anti-tumor necrosis factor-alpha (anti-TNF) therapies are associated with severe mycobacterial infections in rheumatoid arthritis patients. We developed and validated electronic record search algorithms for these serious infections.
METHODS: The study used electronic clinical, microbiologic, and pharmacy records from Kaiser Permanente Northern California (KPNC) and the Portland Veterans Affairs Medical Center (PVAMC). We identified suspect tuberculosis and nontuberculous mycobacteria (NTM) cases using inpatient and outpatient diagnostic codes, culture results, and anti-tuberculous medication dispensing. We manually reviewed records to validate our case-finding algorithms.
RESULTS: We identified 64 tuberculosis and 367 NTM potential cases, respectively. For tuberculosis, diagnostic code positive predictive value (PPV) was 54% at KPNC and 9% at PVAMC. Adding medication dispensings improved these to 87% and 46%, respectively. Positive tuberculosis cultures had a PPV of 100% with sensitivities of 79% (KPNC) and 55% (PVAMC). For NTM, the PPV of diagnostic codes was 91% (KPNC) and 76% (PVAMC). At KPNC, ≥ 1 positive NTM culture was sensitive (100%) and specific (PPV, 74%) if non-pathogenic species were excluded; at PVAMC, ≥1 positive NTM culture identified 76% of cases with PPV of 41%. Application of the American Thoracic Society NTM microbiology criteria yielded the highest PPV (100% KPNC, 78% PVAMC).
CONCLUSIONS: The sensitivity and predictive value of electronic microbiologic data for tuberculosis and NTM infections is generally high, but varies with different facilities or models of care. Unlike NTM, tuberculosis diagnostic codes have poor PPV, and in the absence of laboratory data, should be combined with anti-tuberculous therapy dispensings for pharmacoepidemiologic research.
Copyright © 2010 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21351303      PMCID: PMC4094092          DOI: 10.1002/pds.2049

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  16 in total

1.  A brief introduction to the National Data Bank for Rheumatic Diseases.

Authors:  F Wolfe; K Michaud
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

Review 2.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

3.  Veteran's affairs hospital discharge databases coded serious bacterial infections accurately.

Authors:  Sebastian Schneeweiss; Ari Robicsek; Richard Scranton; Dan Zuckerman; Daniel H Solomon
Journal:  J Clin Epidemiol       Date:  2006-12-18       Impact factor: 6.437

4.  Case definitions for infectious conditions under public health surveillance. Centers for Disease Control and Prevention.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-05-02

5.  Antirheumatic drugs and the risk of tuberculosis.

Authors:  Paul Brassard; Abbas Kezouh; Samy Suissa
Journal:  Clin Infect Dis       Date:  2006-08-10       Impact factor: 9.079

Review 6.  The epidemiology of rheumatoid arthritis.

Authors:  S E Gabriel
Journal:  Rheum Dis Clin North Am       Date:  2001-05       Impact factor: 2.670

7.  Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?

Authors:  Stefan Ehlers
Journal:  Clin Infect Dis       Date:  2005-08-01       Impact factor: 9.079

Review 8.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

9.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

10.  Pharmacy data for tuberculosis surveillance and assessment of patient management.

Authors:  Deborah S Yokoe; Steven W Coon; Rachel Dokholyan; Michael C Iannuzzi; Timothy F Jones; Sarah Meredith; Marisa Moore; Lynelle Phillips; Wayne Ray; Stephanie Schech; Deborah Shatin; Richard Platt
Journal:  Emerg Infect Dis       Date:  2004-08       Impact factor: 6.883

View more
  20 in total

1.  Spatial clusters of nontuberculous mycobacterial lung disease in the United States.

Authors:  Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Joseph O Falkinham; Steven M Holland; D Rebecca Prevots
Journal:  Am J Respir Crit Care Med       Date:  2012-07-05       Impact factor: 21.405

2.  Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population.

Authors:  Theodore K Marras; Christopher Vinnard; Quanwu Zhang; Keith Hamilton; Jennifer Adjemian; Gina Eagle; Raymond Zhang; Engels Chou; Kenneth N Olivier
Journal:  Respir Med       Date:  2018-10-22       Impact factor: 3.415

3.  Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries.

Authors:  Jennifer Adjemian; Kenneth N Olivier; Amy E Seitz; Steven M Holland; D Rebecca Prevots
Journal:  Am J Respir Crit Care Med       Date:  2012-02-03       Impact factor: 21.405

4.  Accuracy of pharmacy and coded-diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis.

Authors:  Christina T Fiske; Marie R Griffin; Ed Mitchel; Timothy R Sterling; Carlos G Grijalva
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-04-24       Impact factor: 2.890

5.  Geographic Distribution of Nontuberculous Mycobacterial Species Identified among Clinical Isolates in the United States, 2009-2013.

Authors:  Alicen B Spaulding; Yi Ling Lai; Adrian M Zelazny; Kenneth N Olivier; Sameer S Kadri; D Rebecca Prevots; Jennifer Adjemian
Journal:  Ann Am Thorac Soc       Date:  2017-11

6.  A population-based study of infection-related hospital mortality in patients with dermatomyositis/polymyositis.

Authors:  Sara G Murray; Gabriela Schmajuk; Laura Trupin; Erica Lawson; Matthew Cascino; Jennifer Barton; Mary Margaretten; Patricia P Katz; Edward H Yelin; Jinoos Yazdany
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

7.  Understanding the burden of tuberculosis among American Indians/Alaska Natives in the U.S.: a validation study.

Authors:  Laura Jean Podewils; Emily Alexy; Stephani Jean Driver; James E Cheek; Robert C Holman; Dana Haberling; Meghan Brett; Eugene McCray; John T Redd
Journal:  Public Health Rep       Date:  2014 Jul-Aug       Impact factor: 2.792

8.  Mortality association of nontuberculous mycobacterial infection requiring treatment in Taiwan: a population-based study.

Authors:  Hsin-Hua Chen; Ching-Heng Lin; Wen-Cheng Chao
Journal:  Ther Adv Respir Dis       Date:  2022 Jan-Dec       Impact factor: 5.158

9.  The Burden of Pulmonary Nontuberculous Mycobacterial Disease in the United States.

Authors:  Sara E Strollo; Jennifer Adjemian; Michael K Adjemian; D Rebecca Prevots
Journal:  Ann Am Thorac Soc       Date:  2015-10

10.  Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study.

Authors:  Mehdi Mirsaeidi; Roberto F Machado; Joe G N Garcia; Dean E Schraufnagel
Journal:  PLoS One       Date:  2014-03-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.